Treatment effects of DC101 and rituximab (RTX) on SKI-DLCL1 lymphoma xenografts
Agent . | Dose . | Average tumor diameter, mm ± SE . | Average tumor volume (TV), mm3 ± SE . | P for TV IVIG vs treatment . |
|---|---|---|---|---|
| IVIG | 800 μg 2×/wk | 13 ± 0.4 | 1083 ± 113 | NA |
| DC101 | 400 μg 3×/wk | 9.9 ± 0.6 | 566 ± 95 | ≤ .003 |
| RTX | 25 μg 2×/wk | 10 ± 0.6 | 568 ± 92 | ≤ .003 |
| DC + RTX | 400 μg 3×/wk and 25 μg 2×/wk | 8.2 ± 0.4 | 298 ± 36 | ≤ .0001 |
Agent . | Dose . | Average tumor diameter, mm ± SE . | Average tumor volume (TV), mm3 ± SE . | P for TV IVIG vs treatment . |
|---|---|---|---|---|
| IVIG | 800 μg 2×/wk | 13 ± 0.4 | 1083 ± 113 | NA |
| DC101 | 400 μg 3×/wk | 9.9 ± 0.6 | 566 ± 95 | ≤ .003 |
| RTX | 25 μg 2×/wk | 10 ± 0.6 | 568 ± 92 | ≤ .003 |
| DC + RTX | 400 μg 3×/wk and 25 μg 2×/wk | 8.2 ± 0.4 | 298 ± 36 | ≤ .0001 |
Mean tumor volume on treatment day 21 is shown (n = 5-10 animals per group). NA indicates not applicable.